title: [Prostate cancer treated with androgen deprivation therapy: Care and monitoring in daily practice].
abstract: OBJECTIVE
  Our purpose was to identify measures implemented by urologists and radiation oncologists at the initiation of a 6-month formulation of luteinizing hormone releasing hormone (LHRH) agonist in patients with advanced PCa.
  
  
  METHODS
  This cross-sectional cohort survey was conducted during 6 months. Participants completed a questionnaire of 15 items on the first prescription of an androgen deprivation therapy (ADT), the parameters prescribed for monitoring and information provided to patients.
  
  
  RESULTS
  The median age of the 1100 enrolled patients was 75 years (range: 51-98 years); 245 patients (29.0%) were metastatic and 411 (39.4%) had a Gleason score ≥ 8. Prior to the treatment initiation, the dosage of the total testosterone was not very often performed (4.8%). Associated comorbidities such as arterial hypertension (53.6%) and hypercholesterolemia (31.8%) did not constitute a barrier to the initiation of ADT, alone (60.5%) or combined with anti-androgens (61%). According to the recommendations of the French Association of Urology (AFU), fasting glycemia was required in 427 patients (41.1%), lipid profile in 380 (36.1%), a blood count in 219 (21.1%) and bone densitometry in 111 (10.8%). The advice given to patients involved diet and lifestyle rules (61%). The potential risks of adverse events (AEs) mentioned were mainly hot flashes (95.5%).
  
  
  CONCLUSIONS
  Some recommendations seem insufficiently followed by the French specialists on information and monitoring procedures of ADT, especially in the cardiovascular field.
authors.affiliation: Service de cancérologie et radiothérapie, hôpital Saint-Louis, 75010 Paris, France. Electronic address: christophe.hennequin2@aphp.fr.
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
authors.affiliation: Service d'urologie, CHRU Bretonneau, Tours, France; PRES, université Val-de-Loire, 37000 Tours, France.
authors.forename: F
authors.initials: F
authors.lastname: Bruyère
authors.affiliation: Société Evidence Based Communication, 92500 Rueil-Malmaison, France.
authors.forename: A
authors.initials: A
authors.lastname: Sedefdjian
authors.affiliation: Astellas Pharma S.A.S, 26 quai Michelet-CS 90067, 92309 Levallois-Perret cedex, France.
authors.forename: R
authors.initials: R
authors.lastname: Bourouina
authors.affiliation: Service d'urologie, hôpital Pitié-Salpêtrière (Assistance publique-Hôpitaux de Paris), 83, boulevard de l'Hôpital, 75013 Paris, France; Institut universitaire de cancérologie, GRC5, oncotype-uro, université Paris 6, 75005 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Rouprêt
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D016903:Drug Monitoring; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011795:Surveys and Questionnaires
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone
keywords: Androgen deprivation therapy; Cancer de la prostate; Effets secondaires; Metastasis; Métastase; Prostate cancer; Recurrence; Récidive; Side effects; Suppression androgénique; Survie; Survival